secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sanara MedTech Inc. (SMTI)
CIK:        0000714256
Form:       8-K
Filed at:   2025-08-13T23:59:59+00:00
Accession:  0001493152-25-011878
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sanara MedTech Q2 revenue up 28% to $25.8M; launches strategic review for Tissue Health Plus subsidiary
--------------------------------------------------------------------------------

- Net revenue $25.8M, up 28% YoY; net loss narrowed to $2.0M from $3.5M.
- Adjusted EBITDA $2.7M vs $0.6M in prior-year quarter.
- H1 2025: revenue $49.3M (+27%), net loss $5.5M, adjusted EBITDA $3.3M.
- Sanara Surgical segment H1 adjusted EBITDA $7.4M vs $2.5M; THP segment adjusted EBITDA -$4.1M vs -$1.6M.
- Company initiates process to evaluate strategic alternatives for Tissue Health Plus subsidiary.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/714256/000149315225011878/0001493152-25-011878-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/714256/000149315225011878/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-011878

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer